Back to News
Market Impact: 0.35
AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
Source: PR Newswire
Healthcare & BiotechCompany Fundamentals
Etentamig reported a significantly improved objective response rate (ORR) of 74% and a 60% reduction in risk of disease progression or death, with progression-free survival showing a hazard ratio of 0.40 versus investigator's choice of standard available therapies.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
More News
- Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs
- Craneware shares plunge 23% after cyber incident, weaker outlook
- Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals
- Volkswagen, Porsche shares extend losses following profit warning
- Societe Generale targets over €21 bln in payouts through 2029
- JPMorgan initiates NexGen Energy stock at Overweight, $14 target
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Portfolio Monitoring: Build an Alert Policy Analysts Can Audit
- The Great Divergence: North American Banking at the Crossroads of Monetary Policy and Agentic AI (Q4 2025 Bank Earnings)